Kunming Longjin Pharmaceutical (SZSE:002750) One-year Losses Have Grown Faster Than Shareholder Returns Have Fallen, but the Stock Surges 21% This Past Week
Kunming Longjin Pharmaceutical (SZSE:002750) One-year Losses Have Grown Faster Than Shareholder Returns Have Fallen, but the Stock Surges 21% This Past Week
Kunming Longjin Pharmaceutical Co., Ltd. (SZSE:002750) shareholders should be happy to see the share price up 21% in the last week. But that doesn't change the reality of under-performance over the last twelve months. In fact, the price has declined 48% in a year, falling short of the returns you could get by investing in an index fund.
昆明龍津藥業有限公司(SZSE:002750)股東應該很高興看到上週股價上漲21%。但這並不能改變過去十二個月中表現不佳的現實。實際上,價格在一年內下跌了48%,未達到投資指數基金所能獲得的回報。
Although the past week has been more reassuring for shareholders, they're still in the red over the last year, so let's see if the underlying business has been responsible for the decline.
儘管過去一週令股東更加放心,但與去年相比,他們仍處於虧損狀態,所以讓我們看看基礎業務是否是造成下降的原因。
Because Kunming Longjin Pharmaceutical made a loss in the last twelve months, we think the market is probably more focussed on revenue and revenue growth, at least for now. When a company doesn't make profits, we'd generally expect to see good revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.
由於昆明龍津製藥在過去十二個月中出現虧損,我們認爲至少目前市場可能更加關注收入和收入增長。當一家公司沒有盈利時,我們通常預計收入會有良好的增長。那是因爲如果收入增長可以忽略不計,而且從來沒有盈利,就很難確信一家公司能否實現可持續發展。
Kunming Longjin Pharmaceutical's revenue didn't grow at all in the last year. In fact, it fell 57%. If you think that's a particularly bad result, you're statistically on the money Meanwhile, the share price dropped by 48%. We would want to see improvements in the core business, and diminishing losses, before getting too excited about this one.
去年,昆明龍津藥業的收入根本沒有增長。實際上,它下降了57%。如果你認爲這是一個特別糟糕的結果,那麼從統計學上講,你是在看錢。同時,股價下跌了48%。在對核心業務過於興奮之前,我們希望看到核心業務的改善和損失的減少。
The image below shows how earnings and revenue have tracked over time (if you click on the image you can see greater detail).
下圖顯示了收入和收入隨時間推移的跟蹤情況(如果您點擊圖片,可以看到更多細節)。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240221/0-ae42def5a72cd290f8fb2160f1fcc425-0-2fc7264a04cd23a89b73ba8fd7dca397.png/big)
Take a more thorough look at Kunming Longjin Pharmaceutical's financial health with this free report on its balance sheet.
通過這份免費的資產負債表報告,更全面地了解昆明龍津製藥的財務狀況。
A Different Perspective
不同的視角
We regret to report that Kunming Longjin Pharmaceutical shareholders are down 48% for the year. Unfortunately, that's worse than the broader market decline of 21%. However, it could simply be that the share price has been impacted by broader market jitters. It might be worth keeping an eye on the fundamentals, in case there's a good opportunity. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 1.4% per year over five years. Generally speaking long term share price weakness can be a bad sign, though contrarian investors might want to research the stock in hope of a turnaround. It's always interesting to track share price performance over the longer term. But to understand Kunming Longjin Pharmaceutical better, we need to consider many other factors. Consider for instance, the ever-present spectre of investment risk. We've identified 2 warning signs with Kunming Longjin Pharmaceutical , and understanding them should be part of your investment process.
我們遺憾地報告,昆明龍津藥業的股東今年下跌了48%。不幸的是,這比整個市場21%的跌幅還要嚴重。但是,可能只是股價受到了更廣泛的市場緊張情緒的影響。如果有很好的機會,可能值得關注基本面。遺憾的是,去年的業績結束了糟糕的表現,股東在五年內每年面臨1.4%的總虧損。總的來說,長期股價疲軟可能是一個壞兆頭,儘管逆勢投資者可能希望研究該股以期出現轉機。長期跟蹤股價表現總是很有意思的。但是,要更好地了解昆明龍津藥業,我們需要考慮許多其他因素。例如,投資風險的幽靈無處不在。我們已經確定了昆明龍津藥業的兩個警告信號,了解它們應該成爲您投資過程的一部分。
But note: Kunming Longjin Pharmaceutical may not be the best stock to buy. So take a peek at this free list of interesting companies with past earnings growth (and further growth forecast).
但請注意:昆明龍津藥業可能不是最好的買入股票。因此,來看看這份過去盈利增長(以及進一步增長預測)的有趣公司的免費清單。
Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.
請注意,本文引用的市場回報反映了目前在中國交易所交易的股票的市場加權平均回報。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。